ECR 2025 Shines a Spotlight on Next-Generation Imaging Innovations
Positive results from Phase III study for Bayer’s investigational contrast agent gadoquatrane
This website uses cookies to give our readers the best website experience. Please refer to our privacy policy to find out how we use cookies and how you can edit your preferences.